For additional information, please visit http://www.raptorpharma.com.
About Patheon Pharmaceuticals Inc.
Patheon (TSX: PTI) is a leading global provider of drug development and manufacturing services to the international pharmaceutical industry. The Company operates a network of 12 facilities in the United States, Canada and Europe, employing more than 4,650 people and serving a global client base of 250 pharmaceutical and biotechnology companies. For further information about Patheon, please visit http://www.patheon.com or contact the company at email@example.com or (905) 821-4001.
FORWARD LOOKING STATEMENTS
This document contains forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements relate to future events or our future results of operation or
future financial performance, including, but not limited to the following
statements: the Company's ability to initiate a Phase 2a study of
Cysteamine or Delayed Release Cysteamine in NASH patients in 2008, develop
an oral formulation of 4MP, develop clinical assays for the oral
formulation of 4MP and initiate a clinical trial for the oral formulation
of 4MP in the second half of 2008. These statements are only predictions
and involve known and unknown risks, uncertainties and other factors, which
may cause our actual results to be materially different from these
forward-looking statements. Factors which may significantly change or
prevent our forward looking statements from fruition include that we may be
unsuccessful in developing any products or acquiring products; that our
technology may not be validated as we progress further and our methods may
not be accepted by the scientific community; that we are unable
|SOURCE Raptor Pharmaceuticals Corp.|
Copyright©2008 PR Newswire.
All rights reserved